Tests LCAR-HL30 cell therapy for returning Hodgkin's and anaplastic large cell lymphoma
Tests LCAR-HL30 cells in adults with relapsed or refractory Hodgkin's or anaplastic large cell lymphoma.
Plain-language title generated from the registry record
Registry title: A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06494371, who can take part
Where in China
- Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT06494371
- Record updated
- 10 July 2024
- Original description
This is a prospective, single-arm, open-label, exploratory clinical study of LCAR-HL30 in adult subjects with relapsed/refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma.Read full original descriptionShow less
An Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of CD30-Targeted LCAR-HL30 Cells in Patients With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
This is a prospective, single-arm, open-label, exploratory clinical study of LCAR-HL30 in adult subjects with relapsed/refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma.
Inclusion: Subjects voluntarily participate in clinical research; Aged 18 to 75 years, either sex; Eastern Cooperative Oncology Group (ECOG) score 0-1 (Dose escalation phase). ECOG score 0-2 (Dose expansion period); Histologically confirmed Hodgkin's lymphoma or Anaplastic large cell lymphoma with positive CD30 expression; At least one evaluable tumor lesion according to Lugano 2014 criteria; Expected survival ≥3 months; Clinical laboratory values in the screening period meet criteria; Effective contraception.
Exclusion: Prior antitumor therapy with insufficient washout period; Previous treatment with CAR-T therapy, allogeneic hematopoietic stem cell transplantation; Severe underlying diseases; Hepatitis B virus surface antigen (HbsAg), Hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C virus ribonucleic acid (HCV RNA) or human immunodeficiency virus antibody (HIV-Ab) positive; Presence of other serious pre-existing medical conditions that may limit patient participation in the study. Any condition that, in the investigator's judgment, will make the subject unsuitable for participation in this study.